World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
91
Citations
63756
World Ranking
11487
National Ranking
5888

Jerry S. Wolinsky publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Jerry S. Wolinsky sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 462 publications — 51st percentile

51% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Jerry S. Wolinsky D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Jerry S. Wolinsky sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 91 D-Index — 43rd percentile

43% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 1996 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Jerry S. Wolinsky is affiliated with The University of Texas Health Science Center at Houston in the United States. Their primary field of study is Medicine, with a focus on several subfields including Pathology and Forensic Medicine, Neurology, Rheumatology, Genetics, and Hematology.

Wolinsky's research broadly covers topics such as Multiple Sclerosis Research Studies, Peripheral Neuropathies and Disorders, Rheumatoid Arthritis Research and Therapies, Chronic Lymphocytic Leukemia Research, Chronic Myeloid Leukemia Treatments, Acute Lymphoblastic Leukemia Research, and Systemic Lupus Erythematosus Research.

Frequent co-authors collaborating with Wolinsky include:

  • Ludwig Kappos
  • Douglas L. Arnold
  • Xavier Montalbán
  • Gary Cutter
  • Fred Lublin

Major publication venues for their work comprise:

  • Neurology
  • Multiple Sclerosis Journal
  • Multiple Sclerosis and Related Disorders
  • Revue Neurologique
  • Multiple Sclerosis Journal - Experimental Translational and Clinical

Recent papers authored or co-authored by Wolinsky demonstrate contributions primarily in multiple sclerosis research. These include:

  • Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial, 2020, The Lancet Neurology
  • Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials, 2020, JAMA Neurology
  • Safety of Ocrelizumab in Patients With Relapsing and Primary Progressive Multiple Sclerosis, 2021, Neurology
  • Five years of ocrelizumab in relapsing multiple sclerosis, 2020, Neurology
  • Diroximel Fumarate Demonstrates an Improved Gastrointestinal Tolerability Profile Compared with Dimethyl Fumarate in Patients with Relapsing-Remitting Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III EVOLVE-MS-2 Study, 2020, CNS Drugs

Jerry S. Wolinsky received recognition as a Fellow of the American Association for the Advancement of Science (AAAS) in 1996.

Best Publications

  • Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

    Chris H Polman;Stephen C Reingold;Brenda Banwell;Michel Clanet

  • Recommended diagnostic criteria for multiple sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis

    W. Ian McDonald;Alistair Compston;Gilles Edan;Donald E Goodkin

  • Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria".

    Chris H. Polman;Stephen C. Reingold;Gilles Edan;Massimo Filippi

  • Defining the clinical course of multiple sclerosis: The 2013 revisions

    Fred D. Lublin;Stephen C. Reingold;Jeffrey A. Cohen;Gary R. Cutter

  • Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis Results of a phase III multicenter, double‐blind, placebo‐controlled trial

    K. P. Johnson;B. R. Brooks;J. A. Cohen;C. C. Ford

  • Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

    Stephen L. Hauser;Amit Bar-Or;Giancarlo Comi;Gavin Giovannoni

  • Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

    Xavier Montalban;Stephen L. Hauser;Ludwig Kappos;Douglas L. Arnold

  • Randomized Trial of Oral Teriflunomide for Relapsing Multiple Sclerosis

    Paul O'Connor;Jerry S Wolinsky;Christian Confavreux;Giancarlo Comi

  • European/Canadian multicenter, double‐blind, randomized, placebo‐controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis

    Giancarlo Comi;Massimo Filippi;Jerry S. Wolinsky

  • Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

    Kenneth P. Johnson;B. R. Brooks;Jeffrey A Cohen;C. C. Ford

  • Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

    Christian Confavreux;Paul O'Connor;Giancarlo Comi;Mark S. Freedman

  • Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials.

    Ludwig Kappos;Jerry S. Wolinsky;Gavin Giovannoni;Douglas L. Arnold

  • Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double-blind, placebo-controlled trial

    Jerry S. Wolinsky;Ponnada A. Narayana;Paul O'Connor;Patricia K. Coyle

  • Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

    Fred Lublin;David H Miller;Mark S Freedman;Bruce A C Cree

  • The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis

    Franz Fazekas;F. Barkhof;M. Filippi;R. I. Grossman

  • Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial:

    Patrick Vermersch;Anna Czlonkowska;Luigi M E Grimaldi;Christian Confavreux

  • Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis.

    Ponnada A. Narayana;Timothy J. Doyle;Dejian Lai;Jerry S. Wolinsky

  • Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines.

    Jack H. Simon;D. Li;A. Traboulsee;P. K. Coyle

  • Isolation of metabolically active capillaries from rat brain.

    G. W. Goldstein;G. W. Goldstein;J. S. Wolinsky;J. S. Wolinsky;Judit Csejtey;Judit Csejtey;I. Diamond;I. Diamond

  • Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis.

    G. M. McKhann;J. W. Griffin;David Cornblath;E. D. Mellits

Frequent Co-Authors

Ludwig Kappos
Ludwig Kappos University Hospital of Basel
Ponnada A. Narayana
Ponnada A. Narayana The University of Texas Health Science Center at Houston
Xavier Montalban
Xavier Montalban Autonomous University of Barcelona
Fred D. Lublin
Fred D. Lublin Icahn School of Medicine at Mount Sinai
Douglas L. Arnold
Douglas L. Arnold Montreal Neurological Institute and Hospital
Stephen L. Hauser
Stephen L. Hauser University of California, San Francisco
Mark S. Freedman
Mark S. Freedman Ottawa Hospital
Giancarlo Comi
Giancarlo Comi Vita-Salute San Raffaele University
Gary Cutter
Gary Cutter University of Alabama at Birmingham
Gavin Giovannoni
Gavin Giovannoni Queen Mary University of London

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in medicine, there are flexible online pathways to advance your career or switch specialties. Many schools now offer online dnp programs without clinicals, designed for working nurses who want to earn terminal degrees without a heavy on-site commitment.

If you’re seeking a quick entry into the medical field, accelerated lpn programs online make it possible to become a Licensed Practical Nurse faster, with coursework that fits busy schedules.

For those drawn to mental healthcare, psych np online programs offer a direct route to advanced nursing roles specializing in psychiatric and mental health services, often with flexible start dates and remote learning options.

Beyond clinical practice, a healthcare administration degree online opens doors to leadership, management, and business roles in healthcare organizations, supporting students who want to shape policy or operational decisions.

Exploring online degrees lets you tailor your education to your goals and lifestyle, making advanced credentials more accessible than ever before.

Best Scientists Citing Jerry S. Wolinsky

Trending Scientists

Recently Published Articles